BRAF and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) guideline recommends broad molecular profiling, including screening for the presence of activating alterations in EGFR, ALK, ROS1, BRAF, KRAS, MET, ERBB2, and RET to inform the selection of effective targeted therapies for NSCLC patients.